161 related articles for article (PubMed ID: 9624495)
1. Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.
Padoin C; Tod M; Perret G; Petitjean O
Antimicrob Agents Chemother; 1998 Jun; 42(6):1463-9. PubMed ID: 9624495
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.
Jacolot A; Tod M; Petitjean O
Antimicrob Agents Chemother; 1996 Apr; 40(4):979-82. PubMed ID: 8849263
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of transport of quinapril in Caco-2 cell monolayers: comparison with cephalexin.
Hu M; Zheng L; Chen J; Liu L; Zhu Y; Dantzig AH; Stratford RE
Pharm Res; 1995 Aug; 12(8):1120-5. PubMed ID: 7494822
[TBL] [Abstract][Full Text] [Related]
4. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Davis JL; Kruger K; LaFevers DH; Barlow BM; Schirmer JM; Breuhaus BA
Equine Vet J; 2014 Nov; 46(6):729-33. PubMed ID: 24175935
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic alterations of quinapril during repeated treatment in elderly subjects.
Sasaki M; Maeda A; Fujimura A
Eur J Clin Pharmacol; 1998 Jun; 54(4):347-9. PubMed ID: 9696962
[TBL] [Abstract][Full Text] [Related]
6. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928.
Ferry JJ; Horvath AM; Sedman AJ; Latts JR; Colburn WA
J Clin Pharmacol; 1987; 27(5):397-9. PubMed ID: 3693584
[TBL] [Abstract][Full Text] [Related]
7. Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations.
Kugler AR; Olson SC; Smith DE
J Pharmacokinet Biopharm; 1996 Aug; 24(4):349-68. PubMed ID: 9044165
[TBL] [Abstract][Full Text] [Related]
8. In vivo kinetics of indoxyl sulfate in humans and its renal interaction with angiotensin-converting enzyme inhibitor quinapril in rats.
Fujita T; Ishihara K; Yasuda S; Nakamura T; Maeda M; Kobayashi M; Sahashi K; Ikeda Y; Kumagai Y; Majima M
J Pharmacol Exp Ther; 2012 Jun; 341(3):626-33. PubMed ID: 22389425
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.
Begg EJ; Robson RA; Bailey RR; Lynn KL; Frank GJ; Olson SC
Br J Clin Pharmacol; 1990 Aug; 30(2):213-20. PubMed ID: 2144994
[TBL] [Abstract][Full Text] [Related]
10. Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.
Kugler AR; Olson SC; Smith DE
J Pharmacokinet Biopharm; 1995 Jun; 23(3):287-305. PubMed ID: 8834197
[TBL] [Abstract][Full Text] [Related]
11. A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
Breslin E; Posvar E; Neub M; Trenk D; Jahnchen E
J Clin Pharmacol; 1996 May; 36(5):414-21. PubMed ID: 8739020
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Fabris B; Chen BZ; Pupic V; Perich R; Johnston CI
J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S6-13. PubMed ID: 1691409
[TBL] [Abstract][Full Text] [Related]
13. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril.
Elliott HL; Macdonald NJ; Meredith PA; Reid JL
Clin Pharmacol Ther; 1992 Mar; 51(3):260-5. PubMed ID: 1312002
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.
Begg EJ; Robson RA; Ikram H; Richards AM; Bammert-Adams JA; Olson SC; Posvar EL; Reece PA; Sedman AJ
Br J Clin Pharmacol; 1994 Mar; 37(3):302-4. PubMed ID: 8198942
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics of captopril, enalapril, and quinapril.
Vertes V; Haynie R
Am J Cardiol; 1992 Apr; 69(10):8C-16C. PubMed ID: 1546641
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment.
Blumer JL; Daniels SR; Dreyer WJ; Batisky D; Walson PD; Roman D; Ouellet D
J Clin Pharmacol; 2003 Feb; 43(2):128-32. PubMed ID: 12616664
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure.
Wolter K; Fritschka E
Eur J Clin Pharmacol; 1993; 44 Suppl 1():S53-6. PubMed ID: 8387427
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
Swartz RD; Starmann B; Horvath AM; Olson SC; Posvar EL
J Clin Pharmacol; 1990 Dec; 30(12):1136-41. PubMed ID: 2273086
[TBL] [Abstract][Full Text] [Related]
19. Effects of the angiotensin-converting enzyme inhibitor quinapril on renal function in rats.
Graziano MJ; Dethloff LA; Griffin HE; Pegg DG
Arch Int Pharmacodyn Ther; 1993; 324():87-104. PubMed ID: 8297189
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of quinapril and its active metabolite, quinaprilat, in patients on chronic hemodialysis.
Blum RA; Olson SC; Kohli RK; Horvath AM; Sedman AJ; Posvar EL
J Clin Pharmacol; 1990 Oct; 30(10):938-42. PubMed ID: 2229454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
